A method for PCR diagnosis of impatiens necrotic spot virus is developed. Concentrated culture fluid with active L-lysine-α-oxidase (0.54 U/ml) from Trichoderma harzianum Rifai fungus producer strain F-180 inhibits vitally hazardous impatiens necrotic spot phytovirus.

01 Sep 2013·British Journal of PharmacologyQ2 · MEDICINE

Pharmacological characterization of FE 201874, the first selective high affinity rat V_1A vasopressin receptor agonist

Q2 · MEDICINE

Article

Author: Desarménien, Michel G ; Virsolvy, Anne ; Haddou, Dominique ; Guillon, Gilles ; Marir, Rafik ; Meraihi, Zahia ; Galibert, Evelyne ; Mion, Julie ; Wisniewski, Kazimierz

Background and PurposeDistinct vasopressin receptors are involved in different physiological and behavioural functions. Presently, no selective agonist is available to specifically elucidate the functional roles of the V1A receptor in the rat, one of the most widely used animal models. FE 201874 is a new derivative of the human selective V1A receptor agonist F180. In this study, we performed a multi‐approach pharmacological and functional characterization of FE 201874 to determine whether it is selective for V1A receptors.Experimental ApproachWe modified an available human selective V1A receptor agonist (F180) and determined its pharmacological properties in cell lines expressing vasopressin/oxytocin receptors (affinity and coupling to second messenger cascades), in an ex vivo model (aorta ring contraction) and in vivo in rats (proliferation of adrenal cortex glomerulosa cells and lactation).Key ResultsFE 201874 exhibited nanomolar affinity for the rat V1A receptor; it was highly selective towards the rat V1B and V2 vasopressin receptors and behaved as a full V1A agonist in all the pharmacological tests performed. FE 201874 bound to the oxytocin receptor, but with moderate affinity, and behaved as an oxytocin antagonist in vitro, but not in vivo.Conclusions and ImplicationsOn functional grounds, all the data demonstrate that FE 201874 is the first selective agonist of the rat V1A receptor isoform available. Hence, FE 201874 may have potential as a treatment for the vasodilator‐induced hypotension occurring in conditions such as septic shock and could be the most suitable compound for discriminating between the behavioural effects of arginine vasopressin and oxytocin.

01 May 2012·Bulletin of Environmental Contamination and ToxicologyQ4 · ENVIRONMENTAL SCIENCE & ECOLOGY

Toxicity of Fuel Oil Water Accommodated Fractions on Two Marine Microalgae, Skeletonema costatum and Chlorela spp

Q4 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Min Chao ; Anglv Shen ; Qi Yuan ; Fengxia Lun ; Xinqiang Shen

In this paper, the acute toxicity of four fuel oils including F120, F180, F380 and No.-20 was evaluated by exposing the marine microalgae Chlorela spp. (Chlorophyta) and Skeletonema costatum (Bacillariophyta) in the fuel oil water accommodated fractions (WAF). The bioassay showed that F180 WAF was the most toxic to both microalgae. The 96 h EC(50) value of F180 WAF for Skeletonema costatum and Chlorela spp. was 9.41 and 13.63 mg/L expressed in concentration of total petroleum hydrocarbons, respectively. WAFs of F120, F180 and F380 were more toxic to Skeletonema costatum than to Chlorela spp. In contrast, No.-20 WAF did not show significant toxicity for both Skeletonema costatum and Chlorela spp.

100 Deals associated with AVPR modulators(Universitat Autònoma de Barcelona)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Phase 3	ES	Universitat Autònoma de Barcelona	-
Liver Cirrhosis	Phase 3	ES	Universitat Autònoma de Barcelona	-
Varicose Veins	Phase 3	ES	Universitat Autònoma de Barcelona	-
Hypertension, Portal	Preclinical	ES	University of Barcelona	01 Feb 1998
Hypertension, Portal	Preclinical	SE	Ferring Research Institute, Inc.	01 Feb 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis